What is enclomiphene?
Enclomiphene citrate is one of the two mirror-image forms that make up clomiphene (Clomid), the fertility drug for women. Clomiphene is a mix of enclomiphene and zuclomiphene. Enclomiphene is the part that acts mainly as an estrogen blocker, and it clears the body within hours, while zuclomiphene has more estrogen-like activity and lingers for weeks.
The idea behind enclomiphene was simple: keep the useful half of clomiphene and drop the half suspected of causing problems. Our page on clomiphene for men explains the parent drug and its side effects.
How does it raise testosterone?
Enclomiphene blocks estrogen receptors in the hypothalamus and pituitary. With estrogen’s “slow down” signal muted, the pituitary releases more LH and FSH. LH tells the testes to make testosterone, and FSH supports sperm production. Your own testes do the work, so the approach only makes sense when they can respond, which is the pattern called secondary hypogonadism.
The main trials showed exactly that. In two phase 3 studies of overweight men aged 18 to 60 with secondary hypogonadism, enclomiphene raised total testosterone, LH and FSH and kept sperm concentrations in the normal range after 16 weeks, while men on testosterone gel reached similar testosterone levels but saw a marked drop in sperm production.
| Enclomiphene | Testosterone therapy | HCG | |
|---|---|---|---|
| How it works | Raises your LH and FSH | Replaces testosterone | Acts like LH on the testes |
| Sperm production | Maintained in trials | Suppressed | Supported |
| FDA-approved for men | No | Yes | Yes, for hypogonadotropic hypogonadism |
| On Ultimate Male’s menu | No | Yes | Yes (Pregnyl) |
It is worth noticing who was studied. Excess body fat converts more testosterone into estradiol, and that extra estrogen feedback is one reason heavier men often have low testosterone with low or normal LH. That is the same group enclomiphene was tested in, and it is also a group in which weight loss alone can lift testosterone. Our page on obesity and low testosterone explains that link.
For a side-by-side look at the two main routes, see our enclomiphene versus TRT comparison.
Why was it never FDA-approved?
Its developer, Repros Therapeutics, applied for approval to treat secondary hypogonadism in overweight men. On November 30, 2015, the FDA issued a complete response letter, meaning the application could not be approved as submitted. According to the company’s announcement, the FDA said the phase 3 design was no longer adequate to show clinical benefit, recommended more phase 3 work, and raised concerns about study entry criteria, dose titration and how drug levels were measured.
No approval has followed. As of October 2026, enclomiphene is not an FDA-approved drug for any use in the United States.
What is its compounding status in 2026?
Without an approval, enclomiphene reaches patients only through compounding pharmacies, and that path is unsettled. Pharmacies compounding under section 503A can use a bulk ingredient only if it meets certain conditions, one of which is being placed on the FDA’s 503A bulks list. Enclomiphene was nominated for that list.
At a June 8, 2022 advisory committee meeting, the FDA proposed that enclomiphene not be added, and the committee voted 8 to 4 against adding it, with several members citing a lack of clinical efficacy evidence. The FDA has not yet published a final decision. Its list of nominated bulk substances, updated May 14, 2026, still shows enclomiphene citrate in Category 1, “under evaluation,” a holding status under which compounding continues while the review is pending.
In plain terms: enclomiphene is not approved, the FDA’s own reviewers and advisers leaned against allowing it in compounding, and its current access depends on an interim status that could end. Capsules sold online as supplements or “research” products fall outside even that.
Side effects and who should avoid it
Because enclomiphene never completed FDA review, there is no approved label listing its side effects, interactions or warnings. Its close relationship to clomiphene means the same concerns are worth watching: vision changes, mood shifts, headache and a rise in estradiol along with testosterone. Long-term safety data in men are limited.
It is a poor fit for men with primary hypogonadism (failing testes), men with known pituitary tumors, and men who compete in tested sport, since the World Anti-Doping Agency prohibited list bans this class of drugs. Sudden vision loss or thoughts of self-harm on any hormone medicine need emergency help: call 911, or call or text 988.
Which options at Ultimate Male protect fertility?
Enclomiphene is not on Ultimate Male’s menu, but the goal behind it, raising testosterone without shutting down sperm production, is one the clinic takes seriously. The AUA guideline states that testosterone should not be given to men currently trying to conceive, and it allows HCG, SERMs or aromatase inhibitors for men who want to keep fertility. At Ultimate Male, that need is met with HCG.
- HCG alone. Pregnyl stimulates the testes directly, raising your own testosterone and supporting sperm production. See HCG therapy for men.
- Testosterone plus HCG, for men who need TRT and want to limit testicular shrinkage and protect fertility as much as possible.
- Testosterone therapy alone, for men whose family is complete or who are not planning children.
The choice starts with labs: total testosterone, LH, an FSH test, estradiol and, when fertility is the priority, a semen analysis as part of the picture. Men already using an estrogen blocker can also read about anastrozole on TRT. To start, see testosterone therapy at Ultimate Male or call 626-319-5261 for a free 10-minute phone call.
